278 related articles for article (PubMed ID: 18303073)
1. Determinants of the rate and extent of spermatogenic suppression during hormonal male contraception: an integrated analysis.
Liu PY; Swerdloff RS; Anawalt BD; Anderson RA; Bremner WJ; Elliesen J; Gu YQ; Kersemaekers WM; McLachlan RI; Meriggiola MC; Nieschlag E; Sitruk-Ware R; Vogelsong K; Wang XH; Wu FC; Zitzmann M; Handelsman DJ; Wang C
J Clin Endocrinol Metab; 2008 May; 93(5):1774-83. PubMed ID: 18303073
[TBL] [Abstract][Full Text] [Related]
2. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
[TBL] [Abstract][Full Text] [Related]
3. Ethnic differences in testicular structure and spermatogenic potential may predispose testes of Asian men to a heightened sensitivity to steroidal contraceptives.
Johnson L; Barnard JJ; Rodriguez L; Smith EC; Swerdloff RS; Wang XH; Wang C
J Androl; 1998; 19(3):348-57. PubMed ID: 9639052
[TBL] [Abstract][Full Text] [Related]
4. Does ethnicity matter in male hormonal contraceptive efficacy?
Ilani N; Liu PY; Swerdloff RS; Wang C
Asian J Androl; 2011 Jul; 13(4):579-84. PubMed ID: 21317912
[TBL] [Abstract][Full Text] [Related]
5. Contraceptive efficacy of a depot progestin and androgen combination in men.
Turner L; Conway AJ; Jimenez M; Liu PY; Forbes E; McLachlan RI; Handelsman DJ
J Clin Endocrinol Metab; 2003 Oct; 88(10):4659-67. PubMed ID: 14557437
[TBL] [Abstract][Full Text] [Related]
6. Rates of suppression and recovery of human sperm output in testosterone-based hormonal contraceptive regimens.
Ly LP; Liu PY; Handelsman DJ
Hum Reprod; 2005 Jun; 20(6):1733-40. PubMed ID: 15860500
[TBL] [Abstract][Full Text] [Related]
7. Relationship between serum gonadotropins and spermatogenic suppression in men undergoing steroidal contraceptive treatment.
McLachlan RI; Robertson DM; Pruysers E; Ugoni A; Matsumoto AM; Anawalt BD; Bremner WJ; Meriggiola C
J Clin Endocrinol Metab; 2004 Jan; 89(1):142-9. PubMed ID: 14715841
[TBL] [Abstract][Full Text] [Related]
8. Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis.
Liu PY; Swerdloff RS; Christenson PD; Handelsman DJ; Wang C;
Lancet; 2006 Apr; 367(9520):1412-20. PubMed ID: 16650651
[TBL] [Abstract][Full Text] [Related]
9. Suppression of spermatogenesis by testosterone enanthate in Thai men.
Aribarg A; Sukcharoen N; Chanprasit Y; Ngeamvijawat J; Kriangsinyos R
J Med Assoc Thai; 1996 Oct; 79(10):624-9. PubMed ID: 8996996
[TBL] [Abstract][Full Text] [Related]
10. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
Behre HM; Nashan D; Hubert W; Nieschlag E
J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
[TBL] [Abstract][Full Text] [Related]
11. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach.
Bebb RA; Anawalt BD; Christensen RB; Paulsen CA; Bremner WJ; Matsumoto AM
J Clin Endocrinol Metab; 1996 Feb; 81(2):757-62. PubMed ID: 8636300
[TBL] [Abstract][Full Text] [Related]
12. Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist.
Page ST; Amory JK; Anawalt BD; Irwig MS; Brockenbrough AT; Matsumoto AM; Bremner WJ
J Clin Endocrinol Metab; 2006 Nov; 91(11):4374-80. PubMed ID: 16940442
[TBL] [Abstract][Full Text] [Related]
13. The influence of pharmaceutical compounds on male fertility.
Neumann F; Diallo FA; Hasan SH; Schenck B; Traore I
Andrologia; 1976; 8(3):203-35. PubMed ID: 793446
[TBL] [Abstract][Full Text] [Related]
14. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5 alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone.
Anderson RA; Wallace AM; Wu FC
J Clin Endocrinol Metab; 1996 Mar; 81(3):902-8. PubMed ID: 8772548
[TBL] [Abstract][Full Text] [Related]
15. Male hormonal contraceptives: current status and future prospects.
Amory JK
Treat Endocrinol; 2005; 4(6):333-41. PubMed ID: 16318399
[TBL] [Abstract][Full Text] [Related]
16. Novel male hormonal contraceptive combinations: the hormonal and spermatogenic effects of testosterone and levonorgestrel combined with a 5alpha-reductase inhibitor or gonadotropin-releasing hormone antagonist.
Matthiesson KL; Amory JK; Berger R; Ugoni A; McLachlan RI; Bremner WJ
J Clin Endocrinol Metab; 2005 Jan; 90(1):91-7. PubMed ID: 15509637
[TBL] [Abstract][Full Text] [Related]
17. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone.
Gonzalo IT; Swerdloff RS; Nelson AL; Clevenger B; Garcia R; Berman N; Wang C
J Clin Endocrinol Metab; 2002 Aug; 87(8):3562-72. PubMed ID: 12161475
[TBL] [Abstract][Full Text] [Related]
18. Testosterone/progestin regimens: a realistic option for male contraception?
Amory JK
Curr Opin Investig Drugs; 2004 Oct; 5(10):1025-30. PubMed ID: 15535423
[TBL] [Abstract][Full Text] [Related]
19. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.
Wallace EM; Gow SM; Wu FC
J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in hormonal male contraception.
Meriggiola MC; Costantino A; Cerpolini S
Contraception; 2002 Apr; 65(4):269-72. PubMed ID: 12020775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
